Adlai Nortye Ltd. (ANL)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase1 Readout | — |
| 2027-07-01 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07252479 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | PHASE1 | Recruiting | 118 |
| NCT04999384 | First in Human, Dose Escalation Study of AN4005 | PHASE1 | Recruiting | 31 |
| NCT07639047 | An Initial Evaluation of AN8025 in Solid Tumors | PHASE1 | Recruiting | 91 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.